AB
Alphyn Biologics develops targeted molecular therapies to treat skin diseases that currently lack effective treatment options. The company focuses on addressing unmet medical needs in dermatology through its proprietary drug mechanisms.
Updated 4 months ago
Funding
$27M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- ```xml
- <problem>
- Existing treatments for atopic dermatitis (AD), the most common form of eczema, often fail to address the underlying bacterial causes and provide comprehensive relief from symptoms like itch and inflammation, leading to a need for therapies suitable for long-term use.</